LianBio Signs $147 Million Deal for Long-Term Rhinosinusitis Product from Lyra

LianBio acquired China rights to a long-term treatment for chronic rhinosinusitis (CRS) from Lyra Therapeutics in an agreement worth up to $147 million. LYR-210 combines a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex to provide six-months of therapy. Lyra positions the product, which is in late-stage trials, as an alternative to surgery for people with CRS that does not respond to other drugs. Formed last year, LianBio is a China in-licensing company that is headquartered in Shanghai and Princeton . More details.... Stock Symbol: (NSDQ: LYRA) Share this with colleagues: // //